NASDAQ · TTRX
Healthcare · Biotechnology
$9.80
Down-$0.27 (-2.68%)
Updated Sep 6, 2026, 7:34 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
TTRX closed at $9.80 after 20 trading sessions, up 2.08% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $9.975 | $10.50 | $9.70 | $9.80 | 70.57K |
| Sep 3, 2026 | $9.67 | $10.4999 | $9.67 | $10.07 | 82.47K |
| Sep 2, 2026 | $9.70 | $10.25 | $9.00 | $9.67 | 106.48K |
| Sep 1, 2026 | $9.60 | $10.285 | $9.28 | $9.82 | 43.21K |
| Aug 31, 2026 | $9.83 | $10.25 | $9.50 | $9.60 | 31.64K |
| Aug 28, 2026 | $10.10 | $10.275 | $9.47 | $9.84 | 62.76K |
| Aug 27, 2026 | $9.54 | $10.25 | $9.51 | $10.11 | 47.6K |
| Aug 26, 2026 | $10.035 | $10.035 | $9.45 | $9.63 | 69.36K |
| Aug 25, 2026 | $9.78 | $10.035 | $9.58 | $9.73 | 31.39K |
| Aug 24, 2026 | $9.39 | $9.87 | $9.04 | $9.68 | 70.26K |
| Aug 21, 2026 | $9.635 | $9.925 | $9.35 | $9.46 | 22.23K |
| Aug 20, 2026 | $9.945 | $10.03 | $9.52 | $9.54 | 32K |
| Aug 19, 2026 | $9.745 | $10.18 | $9.71 | $9.82 | 26.82K |
| Aug 18, 2026 | $9.75 | $10.105 | $9.745 | $9.99 | 20.39K |
| Aug 17, 2026 | $9.83 | $10.13 | $9.58 | $9.91 | 46.02K |
| Aug 14, 2026 | $9.84 | $10.50 | $9.49 | $9.57 | 98.24K |
| Aug 13, 2026 | $10.32 | $10.74 | $9.80 | $9.86 | 64.52K |
| Aug 12, 2026 | $10.30 | $10.9529 | $10.25 | $10.54 | 68.77K |
| Aug 11, 2026 | $9.75 | $10.5699 | $9.63 | $10.22 | 66.41K |
| Aug 10, 2026 | $10.50 | $10.50 | $9.57 | $9.60 | 19.78K |
The latest Smart Investors Daily articles mentioning TTRX.
TTRX research
Company profile and research snapshot.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 24, 2026 | D. Boral Capital | Buy | — |
| Jan 20, 2026 | D. Boral Capital | Buy | — |
| Dec 29, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 20, 2026
In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7%
SeekingAlpha · Jul 15, 2026
Turn Therapeutics offers high risk-reward potential, hinging entirely on its late-stage asset GX-03 for Eczema and Onychomycosis. Click for more on TTRX stock.
Benzinga · Jul 7, 2026
Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.
Benzinga · Jul 7, 2026
Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TTRX.
